Drug details:
Molecular formula: C₂₀H₃₄AuO₉PS

Standard name: gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane

Synonyms:

(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate 1-Thio-|A-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate 1-Thio-beta-D-glucopyranosatotriethyl phosphine gold-2,3,4,6-tetraacetate 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium gold(1+) 3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate triethylphosphane

Curated SMILES: CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]

Evidence for compound's anti-virulence activity:

Clostridium
Related VF: CDT (Clostridium difficile toxin)
Target: Not determined
Drug effect: Inhibits toxin production and spore formation.
Max phase: Preclinical (in vivo)
Publications:
AbdelKhalek A, et al., 2019. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Agents 53(1):54-62.
Hutton ML, et al., 2020. Repurposing auranofin as a Clostridioides difficile therapeutic. J Antimicrob Chemother 75(2):409-417.
Abutaleb NS, et al., 2020. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci Rep 10(1):7701.